Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat pharmacokinetics in healthy Chinese participants
NCT06581627Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of etavopivat in sickle cell disease (SCD) and thalassemia, sponsored by Novo Nordisk. Primary endpoints: Area Under the Plasma Concentration-Time Curve from 0 Hours and Extrapolated to Infinity at 120 hours, Maximum Observed Plasma Concentration at 120 hours and 7 more. Started Aug 2024; status: completed.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT06581627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581627.